Global medical companies join Paddington Life Sciences Partners
Convatec and Ipsen are part of the growing life sciences community around St Mary's Hospital.
Leading life sciences companies, Convatec and Ipsen, have recently joined Paddington Life Sciences Partners. The partnership group brings together NHS, industry, community and academic organisations with a shared commitment to the local community in Paddington and beyond.
The partnership group is a key driver of the Paddington Life Sciences development – a life sciences cluster led by Imperial College Healthcare NHS Trust and centred around St Mary’s Hospital that aims to achieve major health, social and economic value.
Dr Suki Balendra, director of strategic partnerships for Paddington Life Sciences, said: “We are delighted to have Convatec and Ipsen join our partnership. This new collaboration marks a significant milestone for the partnership group which has now grown to 19 members since its inception last year.”
Convatec and Ipsen have agreed to work with the other Paddington Life Sciences Partners to improve health and reduce inequalities through four key areas of focus: social value, diversity and equity in clinical trials, data and digital, and place and space.
Convatec is a key NHS supplier
Convatec is a global medical technology company focused on therapies and products in advanced wound care, ostomy care, continence care and infusion care. The leading MedTech company relocated their global headquarters to Paddington in 2023 and employs more than a thousand people across the UK – around 10% of its global workforce.
Karim Bitar, chief executive officer, Convatec, said:
“We’re delighted to have our global hub in Paddington and to have joined the Paddington Life Sciences partnership. Our presence in London forms part of Convatec’s UK-wide network of customer service; research, innovation and development, and manufacturing locations. We have a rich 45-year heritage serving patients and customers, and supporting people in the UK and around the world. Our Paddington hub is not just about where we work, but how we work to bring to life our vision of pioneering trusted medical solutions to improve the lives we touch and our promise to be forever caring.”
This new partnership builds on an existing relationship between Imperial College Healthcare NHS Trust and Convatec who are an established NHS supplier.
Paddington Life Sciences representatives from the Trust recently had the opportunity to welcome senior leaders from Convatec to St Mary’s Hospital as part of their Global Leaders Meeting in London.
The session was designed to connect Convatec with NHS partners and exchange insights to help Convatec leaders deepen understanding of the NHS landscape and the unmet needs for patients and those who support them.
Ipsen recently relocated to Paddington
Ipsen is a global biopharmaceutical company with a focus on developing medicines in three therapeutic areas: oncology, rare disease and neuroscience.
Last month Ipsen announced that it has opened its new UK headquarters in Paddington as a home for 300 employees.
David Loew, chief executive officer, Ipsen, said:
“Moving our teams into the new global hub in central London builds on 40 years of heritage, marking a new chapter for Ipsen in the UK. Our presence in Paddington further reinforces our continued commitment to the UK, putting us in closer proximity to many key stakeholders. Along with our centre of R&D and manufacturing excellence in Wrexham, the new hub will ensure we continue to deliver on our commitment to bringing innovative medicines to people living with high unmet medical needs.”
Paddington Life Sciences Partners are: British Land, Brockton Everlast, Convatec, Derwent London, Imperial College Healthcare NHS Trust, Imperial College London, Ipsen, IQVIA, Microsoft, Optum, Oracle Health, Takeda, The Paddington Partnership, Vertex and Vodafone. The Associate Partners are: Imperial College Health Partners, Imperial Health Charity, Healthcare Central London and North West London Pathology.
